Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > U.S. adult obesity rate fell in 2023, as use of GLP-1 meds rose
Health and Wellness

U.S. adult obesity rate fell in 2023, as use of GLP-1 meds rose

Last updated: December 13, 2024 5:08 pm
Share
U.S. adult obesity rate fell in 2023, as use of GLP-1 meds rose
SHARE

The findings showed that the obesity rate in the United States decreased from 46.2% in 2021 to 45.6% in 2023. This marks the first decline in the obesity rate in a decade, a significant milestone in the ongoing battle against obesity in the country.

The study, conducted by researchers at Harvard University, analyzed data on almost 17 million adults nationwide. Obesity was defined as having a body mass index (BMI) of 30 or above. The researchers noted that the most significant decrease in obesity was observed in the South, which also had the highest dispensing rate of GLP-1 medications.

GLP-1 medications, such as Wegovy and Zepbound, have seen a surge in use in recent years. These medications have been associated with weight loss, although the researchers cautioned that it is not possible to confirm a cause-and-effect relationship between the decline in obesity rates and the increased use of these medications.

The study, led by Benjamin Rader, an assistant professor of anesthesia at Harvard Medical School, was published in the journal JAMA Health Forum. Rader and his team highlighted the long-standing issue of rising obesity rates in the U.S. and the conflicting forecasts about whether this trend will continue or plateau.

The introduction of GLP-1 medications into the market has introduced a new factor in the fight against obesity. These medications, which mimic a hormone in the intestine that helps regulate appetite, have shown promising results in terms of weight loss. Sales of these medications have soared in recent years, and many individuals have experienced significant weight loss as a result.

See also  GLP-1 Drugs For Weight Loss Aren’t Cost-Saving Yet

The study tracked health insurance data from 2013 through 2023 and focused on adults between the ages of 26 and 75. While the researchers were unable to definitively establish a causal relationship between the decline in obesity rates and the use of GLP-1 medications, the findings suggest that these medications may play a role in addressing the obesity epidemic in the U.S.

Overall, the study provides valuable insights into the complex factors influencing obesity rates in the U.S. and underscores the need for continued research and intervention to combat this ongoing public health challenge.

TAGGED:AdultfellGLP1MedsObesityrateRoseU.S
Share This Article
Twitter Email Copy Link Print
Previous Article Build a website in record time with Squarespace Build a website in record time with Squarespace
Next Article A BROTHERS’ WAR: Unforgiving Prince William Still EXTREMELY Angry With Prodigal Brother Harry, Who Is NOT Invited to the Windsor’s Christmas Celebration in Sandringham | A BROTHERS’ WAR: Unforgiving Prince William Still EXTREMELY Angry With Prodigal Brother Harry, Who Is NOT Invited to the Windsor’s Christmas Celebration in Sandringham |
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Analyst Explains Why Intel (INTC) Will Be a ‘Multibagger’ Stock – ‘No One’s Paying Attention’

In our latest publication titled 10 Must-Watch Tech and AI Stocks Making Waves, Intel Corporation…

October 1, 2025

Should Canada Become the 51st State?

Should Canada Become the 51st State of the United States? Before we delve into the…

February 7, 2025

President Trump’s First Week Hammered Public Health

Fauci will continue to serve as the director of the National Institute of Allergy and…

January 26, 2025

I’m Addicted to my Phone, so I Switched to a Dumb Phone

As the Mobile Editor for Tech Advisor, I am no stranger to the allure of…

April 17, 2025

Crypto theft booms to a record amid kidnappings, Bybit hack

Digital currency thefts have been on the rise, with criminals targeting both crypto platforms and…

July 17, 2025

You Might Also Like

How This Berber Retreat in Morocco’s Atlas Mountains Rose From the Rubble
Lifestyle

How This Berber Retreat in Morocco’s Atlas Mountains Rose From the Rubble

October 10, 2025
STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown
Health and Wellness

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown

October 10, 2025
Gold, Silver, and U.S. Stocks Are All at Record Highs. What Gives?
Economy

Gold, Silver, and U.S. Stocks Are All at Record Highs. What Gives?

October 10, 2025
The Most Infamous Faults in the U.S. May Produce Synchronized Earthquakes
Tech and Science

The Most Infamous Faults in the U.S. May Produce Synchronized Earthquakes

October 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?